STOCK TITAN

Bolt Biotherapeutics (BOLT) Stock News, Jan-Nov 2022

BOLT NASDAQ

Bolt Biotherapeutics develops cancer immunotherapies using its Boltbody™ Immune-Stimulating Antibody Conjugate platform and myeloid-biology programs. Company updates focus on BDC-4182, a next-generation claudin 18.2 ISAC clinical candidate for gastric and gastroesophageal cancers, along with BDC-3042, a Dectin-2 agonist antibody, and preclinical ISAC programs targeting CEA and PD-L1.

Recurring news also includes clinical and preclinical data presentations, quarterly financial results, cash runway commentary, collaboration activity with Genmab and Toray, partnering process disclosures for pipeline assets, conference participation, and cost-control actions tied to the company’s oncology research and development strategy.

Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) will participate in the Stifel 2022 Healthcare Conference on Nov. 16, 2022, at 1:15 p.m. EST in New York. The event will feature a fireside chat with management, and a live webcast can be accessed on Bolt's website. The company is known for developing innovative immuno-oncology therapeutics, including BDC-1001 and BDC-3042, which target HER2 and modulate myeloid biology, respectively. Archived replays will be available for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences
-
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focusing on immuno-oncology, announced participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference.

The event will take place on September 13, 2022, at 12:20 p.m. ET in New York City. A live webcast will be accessible on Bolt's website, with archived replays available for 30 days post-event.

Bolt's pipeline includes innovative therapies targeting cancer, highlighting their commitment to advancing treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
conferences
-
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2022 financial results, highlighting $223.6 million in cash to fund operations through 2025. Clinical progress includes the ongoing BDC-1001 dosage studies, with anticipated data readouts later this year. The company has prioritized its pipeline, ceasing BDC-2034 due to off-target toxicity, while focusing on BDC-1001 and BDC-3042. Collaboration revenue rose to $1.4 million, a 75% increase from Q1 2022. R&D expenses fell slightly to $18.9 million, while G&A expenses rose to $5.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.35%
Tags
Rhea-AI Summary

Bolt Biotherapeutics announces a presentation at the 2022 ASCO Annual Meeting in Chicago, showcasing data on myeloid cell presence in solid tumors, even with low T cell infiltration. The poster, titled "Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs)," highlights myeloid cells' potential as therapeutic targets. The insights could enhance the efficacy of myeloid-targeted therapies, benefiting patients resistant to T cell approaches. The abstract number is 2557, and the poster session is scheduled for June 5.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
-
Rhea-AI Summary

Bolt Biotherapeutics reported Q1 2022 financial results, showing collaboration revenue of $0.8 million, driven by R&D partnerships. R&D expenses rose to $18.4 million, reflecting progress in clinical trials and IND-enabling activities. General and administrative expenses increased to $6.3 million. The company holds a robust cash balance of $246.8 million, expected to fund operations and key milestones into 2024. The lead program, BDC-1001, is on track for data readouts in H2 2022, with promising early signs of clinical disease control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
-
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotech firm, will present an overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 12:45 p.m. PT. The presentation will highlight Bolt's innovative immuno-oncology therapeutics that utilize Boltbody™ to target tumors. Key products include BDC-1001, a HER2-targeting agent in a Phase 1/2 trial, and others targeting CEA and Dectin-2. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
conferences
Rhea-AI Summary

Bolt Biotherapeutics (BOLT) reported its financial results for Q4 and the full year 2021, showcasing a cash balance of $271.6 million to fund operations through 2024. The company is progressing with BDC-1001, a treatment for HER2-expressing solid tumors, expected to reach Phase 2 dose identification later in 2022. The ongoing combination study with OPDIVO® is advancing well, showing promising stability and partial responses. R&D expenses rose to $75.7 million, reflecting increased clinical trial costs. Total revenue for 2021 was $1.3 million, marking growth from $0.2 million in 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
-
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) will present three preclinical pipeline programs at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The company is focused on immuno-oncology therapeutics combining antibody precision with immune system power. Key presentations include BDC-2034, targeting CEA, expected to enter clinical development in late 2022; BDC-3042, a Dectin-2 targeting antibody anticipated for 2023; and a PD-L1-targeting ISAC. Each program shows promise in anti-tumor activity and future clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.20%
Tags
conferences
-
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology firm, recently announced upcoming presentations at two key conferences in February 2022. The first is the Guggenheim 2022 Oncology Virtual Conference on February 9 at 10:00 a.m. PT, followed by the SVB Leerink Global Healthcare Conference on February 16 at 2:00 p.m. PT. Both events will feature fireside chats, available for live streaming on Bolt's website, with archived replays accessible for 90 days post-event.

Bolt focuses on innovative immuno-oncology agents, particularly its lead candidate, BDC-1001, targeting HER2-expressing tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
conferences
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) announced the first patient has been dosed in a new combination arm of its Phase 1/2 clinical trial for BDC-1001, which is being evaluated alongside Bristol Myers Squibb’s OPDIVO® (nivolumab). This trial targets HER2-expressing solid tumors. Preliminary findings from the single-agent portion showed a safe profile, supporting the promising potential of BDC-1001. Bristol Myers Squibb is providing OPDIVO for the trial, while Bolt is responsible for execution costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.95%
Tags

FAQ

What is the current stock price of Bolt Biotherapeutics (BOLT)?

Bolt Biotherapeutics (BOLT) last closed at $5.65.

What is the market cap of Bolt Biotherapeutics (BOLT)?

The market cap of Bolt Biotherapeutics (BOLT) is approximately $14.7M.